Panavance Therapeutics Inc.

Panavance Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company developing a novel small molecule GP-2250. GP-2250 is a tumor cell selective and broadly active agent with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death. GP-2250 is currently in a multi-center Phase 1 trial.

Panavance is advancing towards pivotal Phase 2/3 clinical trials, projected to start in the first half of 2024, in platinum-resistant ovarian cancer and as a first-line maintenance therapy for pancreatic cancer in non-BRCA mutation patients (a population for which there are no FDA approved agents). Based on preclinical activity, GP-2250 has broad oncology applications and has the potential to be effective in additional indications, including melanoma, SCC, breast and colorectal cancers. As we advance to registration directed trials in ovarian and pancreatic tumors in 1H24, we are looking for investors or a strategic partner.